1
|
Wang X, Chen Y, Cheng X, Wang SQ, Hu Y, Feng Y, Jin R, Zhou K, Liu T, Wang J, Pan K, Liu B, Xiang J, Wang Y, Zhou Q, Zhang Y, Pan W, Li W. CDetection.v2: One-pot assay for the detection of SARS-CoV-2. Front Microbiol 2023; 14:1158163. [PMID: 37032875 PMCID: PMC10076661 DOI: 10.3389/fmicb.2023.1158163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Accepted: 03/06/2023] [Indexed: 04/11/2023] Open
Abstract
Introduction The ongoing 2019 coronavirus disease pandemic (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants, is a global public health threat. Early diagnosis and identification of SARS-CoV-2 and its variants plays a critical role in COVID-19 prevention and control. Currently, the most widely used technique to detect SARS-CoV-2 is quantitative reverse transcription real-time quantitative PCR (RT-qPCR), which takes nearly 1 hour and should be performed by experienced personnel to ensure the accuracy of results. Therefore, the development of a nucleic acid detection kit with higher sensitivity, faster detection and greater accuracy is important. Methods Here, we optimized the system components and reaction conditions of our previous detection approach by using RT-RAA and Cas12b. Results We developed a Cas12b-assisted one-pot detection platform (CDetection.v2) that allows rapid detection of SARS-CoV-2 in 30 minutes. This platform was able to detect up to 5,000 copies/ml of SARS-CoV-2 without cross-reactivity with other viruses. Moreover, the sensitivity of this CRISPR system was comparable to that of RT-qPCR when tested on 120 clinical samples. Discussion The CDetection.v2 provides a novel one-pot detection approach based on the integration of RT-RAA and CRISPR/Cas12b for detecting SARS-CoV-2 and screening of large-scale clinical samples, offering a more efficient strategy for detecting various types of viruses.
Collapse
Affiliation(s)
- Xinge Wang
- State Key Laboratory of Stem Cell and Reproductive Biology, Chinese Academy of Sciences, Institute of Zoology, Beijing, China
- Bejing Institute for Stem Cell and Regenerative Medicine, Beijing, China
- Chinese Academy of Sciences, Institute for Stem Cell and Regenerative Medicine, Beijing, China
- Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China
| | - Yangcan Chen
- State Key Laboratory of Stem Cell and Reproductive Biology, Chinese Academy of Sciences, Institute of Zoology, Beijing, China
- Bejing Institute for Stem Cell and Regenerative Medicine, Beijing, China
- Chinese Academy of Sciences, Institute for Stem Cell and Regenerative Medicine, Beijing, China
- Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China
| | - Xuejia Cheng
- Beijing SynsorBio Technology Co., Ltd., Beijing, China
| | - Si-Qi Wang
- State Key Laboratory of Stem Cell and Reproductive Biology, Chinese Academy of Sciences, Institute of Zoology, Beijing, China
- Bejing Institute for Stem Cell and Regenerative Medicine, Beijing, China
- Chinese Academy of Sciences, Institute for Stem Cell and Regenerative Medicine, Beijing, China
| | - Yanping Hu
- State Key Laboratory of Stem Cell and Reproductive Biology, Chinese Academy of Sciences, Institute of Zoology, Beijing, China
- Bejing Institute for Stem Cell and Regenerative Medicine, Beijing, China
- Chinese Academy of Sciences, Institute for Stem Cell and Regenerative Medicine, Beijing, China
- Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China
| | - Yingmei Feng
- Department of Science and Technology, Beijing Youan Hospital, Capital Medical University, Beijing, China
| | - Ronghua Jin
- Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Kangping Zhou
- Hubei Provincial Center for Disease Control and Prevention, Wuhan, China
| | - Ti Liu
- Shandong Center for Disease Control and Prevention, Jinan, China
| | - Jianxing Wang
- Shandong Center for Disease Control and Prevention, Jinan, China
| | - Kai Pan
- Hubei Provincial Center for Disease Control and Prevention, Wuhan, China
| | - Bing Liu
- Tonghua Central Hospital, Tonghua, Jilin, China
| | - Jie Xiang
- Tongji Medical College of Huazhang, Wuhan Jinyintan Hospital, University of Science and Technology, Wuhan, China
| | - Yanping Wang
- Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, China
| | - Qi Zhou
- State Key Laboratory of Stem Cell and Reproductive Biology, Chinese Academy of Sciences, Institute of Zoology, Beijing, China
- Bejing Institute for Stem Cell and Regenerative Medicine, Beijing, China
- Chinese Academy of Sciences, Institute for Stem Cell and Regenerative Medicine, Beijing, China
- Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China
| | - Ying Zhang
- State Key Laboratory of Stem Cell and Reproductive Biology, Chinese Academy of Sciences, Institute of Zoology, Beijing, China
- Bejing Institute for Stem Cell and Regenerative Medicine, Beijing, China
- Chinese Academy of Sciences, Institute for Stem Cell and Regenerative Medicine, Beijing, China
| | - Weiye Pan
- Beijing SynsorBio Technology Co., Ltd., Beijing, China
- Weiye Pan,
| | - Wei Li
- State Key Laboratory of Stem Cell and Reproductive Biology, Chinese Academy of Sciences, Institute of Zoology, Beijing, China
- Bejing Institute for Stem Cell and Regenerative Medicine, Beijing, China
- Chinese Academy of Sciences, Institute for Stem Cell and Regenerative Medicine, Beijing, China
- Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China
- *Correspondence: Wei Li,
| |
Collapse
|
2
|
Chen B, Li Y, Xu F, Yang X. Powerful CRISPR-Based Biosensing Techniques and Their Integration With Microfluidic Platforms. Front Bioeng Biotechnol 2022; 10:851712. [PMID: 35284406 PMCID: PMC8905290 DOI: 10.3389/fbioe.2022.851712] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Accepted: 01/24/2022] [Indexed: 12/20/2022] Open
Abstract
In the fight against the worldwide pandemic coronavirus disease 2019 (COVID-19), simple, rapid, and sensitive tools for nucleic acid detection are in urgent need. PCR has been a classic method for nucleic acid detection with high sensitivity and specificity. However, this method still has essential limitations due to the dependence on thermal cycling, which requires costly equipment, professional technicians, and long turnover times. Currently, clustered regularly interspaced short palindromic repeats (CRISPR)-based biosensors have been developed as powerful tools for nucleic acid detection. Moreover, the CRISPR method can be performed at physiological temperature, meaning that it is easy to assemble into point-of-care devices. Microfluidic chips hold promises to integrate sample processing and analysis on a chip, reducing the consumption of sample and reagent and increasing the detection throughput. This review provides an overview of recent advances in the development of CRISPR-based biosensing techniques and their perfect combination with microfluidic platforms. New opportunities and challenges for the improvement of specificity and efficiency signal amplification are outlined. Furthermore, their various applications in healthcare, animal husbandry, agriculture, and forestry are discussed.
Collapse
Affiliation(s)
- Bing Chen
- Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Ya Li
- Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Feng Xu
- Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- *Correspondence: Feng Xu, ; Xiaonan Yang,
| | - Xiaonan Yang
- Institute of Intelligent Sensing, Zhengzhou University, Zhengzhou, China
- *Correspondence: Feng Xu, ; Xiaonan Yang,
| |
Collapse
|
3
|
Arizti-Sanz J, Bradley A, Zhang YB, Boehm CK, Freije CA, Grunberg ME, Kosoko-Thoroddsen TSF, Welch NL, Pillai PP, Mantena S, Kim G, Uwanibe JN, John OG, Eromon PE, Kocher G, Gross R, Lee JS, Hensley LE, Happi CT, Johnson J, Sabeti PC, Myhrvold C. Equipment-free detection of SARS-CoV-2 and Variants of Concern using Cas13. MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES 2021:2021.11.01.21265764. [PMID: 34751276 PMCID: PMC8575147 DOI: 10.1101/2021.11.01.21265764] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The COVID-19 pandemic, and the recent rise and widespread transmission of SARS-CoV-2 Variants of Concern (VOCs), have demonstrated the need for ubiquitous nucleic acid testing outside of centralized clinical laboratories. Here, we develop SHINEv2, a Cas13-based nucleic acid diagnostic that combines quick and ambient temperature sample processing and lyophilized reagents to greatly simplify the test procedure and assay distribution. We benchmarked a SHINEv2 assay for SARS-CoV-2 detection against state-of-the-art antigen-capture tests using 96 patient samples, demonstrating 50-fold greater sensitivity and 100% specificity. We designed SHINEv2 assays for discriminating the Alpha, Beta, Gamma and Delta VOCs, which can be read out visually using lateral flow technology. We further demonstrate that our assays can be performed without any equipment in less than 90 minutes. SHINEv2 represents an important advance towards rapid nucleic acid tests that can be performed in any location.
Collapse
Affiliation(s)
- Jon Arizti-Sanz
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA 02142, USA
- Harvard-MIT Program in Health Sciences and Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
| | - A’Doriann Bradley
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA 02142, USA
| | - Yibin B. Zhang
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA 02142, USA
- Department of Organismic and Evolutionary Biology, Harvard University, 26 Oxford Street, Cambridge, MA 02138, USA
| | - Chloe K. Boehm
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA 02142, USA
- Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA
| | - Catherine A. Freije
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA 02142, USA
| | - Michelle E. Grunberg
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA 02142, USA
- Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA
| | | | - Nicole L. Welch
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA 02142, USA
- Program in Virology, Harvard Medical School, Boston, MA 02115, USA
| | - Priya P. Pillai
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA 02142, USA
| | - Sreekar Mantena
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA 02142, USA
| | - Gaeun Kim
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA 02142, USA
- Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA
| | - Jessica N. Uwanibe
- African Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer’s University, Ede, Osun State, Nigeria
- Department of Biological Sciences, College of Natural Sciences, Redeemer’s University, Ede, Osun State, Nigeria
| | - Oluwagboadurami G. John
- Department of Biological Sciences, College of Natural Sciences, Redeemer’s University, Ede, Osun State, Nigeria
| | - Philomena E. Eromon
- African Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer’s University, Ede, Osun State, Nigeria
| | - Gregory Kocher
- Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and infectious diseases, National Institute of Health, Frederick, MD 21702, USA
| | - Robin Gross
- Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and infectious diseases, National Institute of Health, Frederick, MD 21702, USA
| | - Justin S. Lee
- Biotechnology Cores Facility Branch,Division of Scientific Resources, National Center for Emerging and Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Lisa E. Hensley
- Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and infectious diseases, National Institute of Health, Frederick, MD 21702, USA
| | - Christian T. Happi
- African Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer’s University, Ede, Osun State, Nigeria
- Department of Biological Sciences, College of Natural Sciences, Redeemer’s University, Ede, Osun State, Nigeria
- Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA
| | - Jeremy Johnson
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA 02142, USA
| | - Pardis C. Sabeti
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA 02142, USA
- Department of Organismic and Evolutionary Biology, Harvard University, 26 Oxford Street, Cambridge, MA 02138, USA
- Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA
- Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA
- These authors jointly supervised this work: Pardis C. Sabeti, Cameron Myhrvold
| | - Cameron Myhrvold
- Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA
- These authors jointly supervised this work: Pardis C. Sabeti, Cameron Myhrvold
| |
Collapse
|
4
|
Mahas A, Wang Q, Marsic T, Mahfouz MM. A Novel Miniature CRISPR-Cas13 System for SARS-CoV-2 Diagnostics. ACS Synth Biol 2021; 10:2541-2551. [PMID: 34546709 PMCID: PMC8482783 DOI: 10.1021/acssynbio.1c00181] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2021] [Indexed: 12/12/2022]
Abstract
Rapid, point-of-care (POC) diagnostics are essential to mitigate the impacts of current (and future) epidemics; however, current methods for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) require complicated laboratory tests that are generally conducted off-site and require substantial time. CRISPR-Cas systems have been harnessed to develop sensitive and specific platforms for nucleic acid detection. These detection platforms take advantage of CRISPR enzymes' RNA-guided specificity for RNA and DNA targets and collateral trans activities on single-stranded RNA and DNA reporters. Microbial genomes possess an extensive range of CRISPR enzymes with different specificities and levels of collateral activity; identifying new enzymes may improve CRISPR-based diagnostics. Here, we identified a new Cas13 variant, which we named as miniature Cas13 (mCas13), and characterized its catalytic activity. We then employed this system to design, build, and test a SARS-CoV-2 detection module coupling reverse transcription loop-mediated isothermal amplification (RT-LAMP) with the mCas13 system to detect SARS-CoV-2 in synthetic and clinical samples. Our system exhibits sensitivity and specificity comparable to other CRISPR systems. This work expands the repertoire and application of Cas13 enzymes in diagnostics and for potential in vivo applications, including RNA knockdown and editing. Importantly, our system can be potentially adapted and used in large-scale testing for diverse pathogens, including RNA and DNA viruses, and bacteria.
Collapse
Affiliation(s)
- Ahmed Mahas
- Laboratory for Genome Engineering and Synthetic Biology, Division of
Biological Sciences, 4700 King Abdullah University of Science and
Technology, Thuwal 23955-6900, Saudi Arabia
| | - Qiaochu Wang
- Laboratory for Genome Engineering and Synthetic Biology, Division of
Biological Sciences, 4700 King Abdullah University of Science and
Technology, Thuwal 23955-6900, Saudi Arabia
| | - Tin Marsic
- Laboratory for Genome Engineering and Synthetic Biology, Division of
Biological Sciences, 4700 King Abdullah University of Science and
Technology, Thuwal 23955-6900, Saudi Arabia
| | - Magdy M. Mahfouz
- Laboratory for Genome Engineering and Synthetic Biology, Division of
Biological Sciences, 4700 King Abdullah University of Science and
Technology, Thuwal 23955-6900, Saudi Arabia
| |
Collapse
|